TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32310699
Drug: Morphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine treatment without metoclopramide
Study: 32310699
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no morphine treatment)
Study: 32312893
Drug: Sunitinib (multi-kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (multi-kinase inhibitor)
Study: 32312891
Drug: Capivasertib monotherapy
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capivasertib monotherapy
Study: 32312891
Drug: Capivasertib in
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capivasertib in combination with Fulvestrant
Study: 32313451
Drug: Latiglutenase (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latiglutenase (900 mg)
Study: 32313731
Drug: Heat shock
Normalized name: Human heat shock protein antigen 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat shock protein peptide complex-96 (HSPPC-96) vaccine
Study: 32314268
Drug: Copanlisib (0.2-0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copanlisib (0.2-0.8 mg/kg intravenously) intermittently or weekly; Refametinib (30-50 mg twice daily orally) continuously or 4 days on/3 days off.
Study: 32315434
Drug: Laser interstitial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser interstitial thermal therapy (LITT) using Robotic NeuroBlate System
Study: 32316080
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray (28-mg, 56-mg, or 84-mg) plus new oral antidepressant (OAD) administered twice a week for 4 weeks, followed by weekly or every-other-week for responders during a 48-week optimization/maintenance phase.
Study: 32316080
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray plus new OAD
Study: 32316977
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy with customized forces
Study: 32317004
Drug: Vitamin C,
Normalized name: Vitamin C, sodium salt
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C, Thiamine and Steroids
Study: 32318062
Drug: CCR4 targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCR4 targeting intervention, details on dosage and duration not available
Study: 32318268
Drug: High-dose meropenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose meropenem (2-g infusion over 3 h every 8 h)
Study: 32318268
Drug: Standard-dose meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose meropenem (1-g infusion over 3 h every 8 h)
Study: 32318268
Drug: Standard-dose meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose meropenem
Study: 32318271
Drug: ThrIVe-B programme
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThrIVe-B programme (psychological therapy)
Study: 32318621
Drug: Blarcamesine (ANAVEX2-73),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blarcamesine (ANAVEX2-73), a selective sigma-1 receptor agonist, administered over a 57-week Phase 2a trial.
Study: 32319040
Drug: Posaconazole 300
Normalized name: posaconazole 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole 300 mg twice daily on day 1 and then once daily for up to 28 days
Study: 32319040
Drug: Posaconazole 300
Normalized name: posaconazole 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole 300 mg tablet
Study: 32319144
Drug: Dietary supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplements (DSs), average 9.12 (SD = 6.46) prescription drugs daily, 25 of 40 participants (62.5%) reported taking ≥1 DS daily.
Study: 32319144
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (part of clinical trial), specific dosage and duration not mentioned.
Study: 32321635
Drug: Old and
Normalized name: Cold and Hot
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old and new antirheumatic drugs
Study: 32323313
Drug: Functional competence
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional competence on PASS (Cognitively Mediated Instrumental Activities of Daily Living)
Study: 32324927
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa (3, 10, and 20 mg/kg every 2 weeks)
Study: 32324981
Drug: Revefenacin 175
Normalized name: REVEFENACIN 175MCG/3ML INHL SOLN 3ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revefenacin 175 µg + Formoterol 20 µg
Study: 32324981
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Formoterol 20 µg
Study: 32324981
Drug: Revefenacin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revefenacin + Formoterol (combined administration)
Study: 32324981
Drug: Formoterol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol alone (evening administration)
Study: 32325037
Drug: MVA-MERS-S vaccine
Normalized name: MVA-SARS-2-S
DrugBank: MVA-SARS-2-S (DB16432)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-MERS-S vaccine
Study: 32325043
Drug: Parenteral anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral anticoagulation only
Study: 32325171
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan (200 mg/m2) for conditioning prior to ASCT
Study: 32325220
Drug: SC-003 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC-003 antibody Fab fragment
Study: 32325461
Drug: Post-Transplantation Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-Transplantation Cyclophosphamide (PTCy) and Ruxolitinib (45 mg from day-7 to day-2, 15 mg from day+5 to day+100)
Study: 32325480
Drug: GSK3050002 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3050002 at 30 mg/kg/week
Study: 32325480
Drug: GSK3050002 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3050002 at 300 mg/kg/week
Study: 32327102
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (n=7)
Study: 32327102
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (n=29)
Study: 32327472
Drug: TAK-659, 60-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-659, 60-120 mg, once-daily oral administration in 28-day cycles until disease progression or unacceptable toxicity
Study: 32328115
Drug: Omalizumab 8
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab 8 mg/kg per month (n=36)
Study: 32328115
Drug: Omalizumab 16
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab 16 mg/kg per month (n=36)
Study: 32328660
Drug: Tepotinib 215,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepotinib 215, 300 or 500 mg once daily
Study: 38575731
Drug: Tepotinib 500
Normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tepotinib 500 mg once daily
Study: 39037964
Drug: Ibrutinib treatment
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib treatment
Study: 32329093
Drug: Fractional CO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO treatment
Study: 32329527
Drug: Lacosamide as
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide as add-on therapy
Study: 32330099
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy and intraventricular methotrexate
Study: 32330102
Drug: Omission of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omission of peg-filgrastim during dose-dense paclitaxel regimen
Study: 32330242
Drug: Pexidartinib (PLX3397)
Normalized name: pexidartinib
DrugBank: Pexidartinib (DB12978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pexidartinib (PLX3397) at doses of 800 to 5000 mg per day
Study: 32330242
Drug: Pexidartinib (PLX3397)
Normalized name: pexidartinib
DrugBank: Pexidartinib (DB12978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pexidartinib (PLX3397) at doses of ≥2000 mg
Study: 32330242
Drug: Pexidartinib (PLX3397)
Normalized name: pexidartinib
DrugBank: Pexidartinib (DB12978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pexidartinib (PLX3397) in dose expansion
Study: 32330244
Drug: Eltrombopag (EPAG)
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag (EPAG) administered at doses escalating from 50 to 300 mg/d.
Study: 32330510
Drug: Gliclazide modified
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide modified release (MR), taken once daily for 14-18 weeks.
Study: 32331767
Drug: BRCA positive
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRCA positive women after chemotherapy treatment
Study: 32331767
Drug: BRCA negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRCA negative women after chemotherapy treatment
Study: 32331767
Drug: Untested/low risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untested/low risk controls after chemotherapy treatment
Study: 32331767
Drug: Before chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before chemotherapy treatment AMH levels in BRCA positive and negative women
Study: 32331936
Drug: Alirocumab 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 40 mg (<50 kg) or 75 mg (≥50 kg) every 2 weeks (Q2W)
Study: 32331936
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg (<50 kg) or 300 mg (≥50 kg) every 4 weeks (Q4W)
Study: 32333591
Drug: Donepezil (Cholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (Cholinesterase Inhibitor) started at 5 mg daily, increased to 10 mg daily if tolerated, maintained for 52 weeks.
Study: 32333591
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in UPSIT score from 0 to 8 weeks with Donepezil treatment.
Study: 32333853
Drug: Warfarin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin for 18 months after initial 6 months treatment
Study: 32333853
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 18 months after initial 6 months treatment
Study: 32334566
Drug: Preoperative serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative serum HDL < 1.03 mmol/L
Study: 32334566
Drug: Preoperative serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative serum HDL > 1.03 mmol/L
Study: 32335374
Drug: Vorolanib 200
Normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorolanib 200 mg plus everolimus 5 mg once daily
Study: 32335374
Drug: Vorolanib 100
Normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorolanib 100 mg plus everolimus 5 mg once daily
Study: 32335374
Drug: Vorolanib 150
Normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorolanib 150 mg plus everolimus 5 mg once daily
Study: 32336987
Drug: EMOTION intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMOTION intervention (transdiagnostic indicated preventive cognitive behavioral therapy)
Study: 32337054
Drug: anti-TNFα therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-TNFα therapy
Study: 32337059
Drug: 1.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/day of phosphatidylcholine (PPC) as adjunctive treatment to standard care
Study: 32337094
Drug: Erlotinib, cetuximab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib, cetuximab, and bevacizumab (triplet combination)
Study: 32337475
Drug: 22 g
Normalized name: Empty Carpuject 2 mL 22 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 g freeze-dried blueberries for 8 weeks
Study: 32337496
Drug: Talazoparib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib (1 mg)
Study: 32337496
Drug: Physician's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's Choice of Chemotherapy (PCT)
Study: 32338433
Drug: rAHF 2
Normalized name: rAHF
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAHF 2 mL prophylaxis
Study: 32338433
Drug: rAHF 2
Normalized name: rAHF
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAHF 2 mL treatment
Study: 32338621
Drug: Home-based rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based rehabilitation program driven by a tablet app and remote coaching (12-week program, exercises at least 5 days a week)
Study: 32338621
Drug: Home-based rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based rehabilitation program driven by a tablet app and remote coaching
Study: 32342016
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) combined with music therapy (10 therapy sessions and related homework)
Study: 32342831
Drug: Dabigatran treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran treatment initiated within 14 days of TIA/minor stroke
Study: 32343640
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg plus Nivolumab 3 mg/kg
Study: 32343640
Drug: Regorafenib 80
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 80 mg plus Nivolumab 3 mg/kg
Study: 32343640
Drug: Regorafenib 120
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 120 mg plus Nivolumab 3 mg/kg
Study: 32344296
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss (±5% between diagnosis and post-treatment)
Study: 32345378
Drug: Opicapone 50
Normalized name: opicapone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 50 mg (UK subgroup)
Study: 32346071
Drug: nab-paclitaxel 100
Normalized name: paclitaxel 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel 100 mg/smq on days 1, 8, 15 every 4 weeks up to six cycles, progressive disease or intolerable toxicity
Study: 32346484
Drug: Home-based prehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based prehabilitation exercise intervention (increasing daily step-count during and after NAC)
Study: 32347439
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for symptomatic children under five
Study: 32349020
Drug: Heterogeneous dose-escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterogeneous dose-escalated prostate stereotactic body radiation therapy (target volume received 36.25 Gy/5 fx; target >3 mm from sensitive structures escalated to 50 Gy/5 fx)
Study: 32349020
Drug: Heterogeneous dose-escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterogeneous dose-escalated prostate stereotactic body radiation therapy
Study: 32349119
Drug: Escitalopram (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (8 weeks of open-label treatment)
Study: 32350529
Drug: Empiric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric treatment (antibiotics and/or antifungals)
Study: 32350529
Drug: Inappropriate prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate prescriptions
Study: 32351419
Drug: Drug-induced parkinsonism
Normalized name: rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-induced parkinsonism
Study: 32352498
Drug: Nivolumab, 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab, 240 mg intravenously every 2 weeks for 16 weeks, then 480 mg every 4 weeks until disease progression or unacceptable toxic effects.
Study: 32352586
Drug: Digital medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital medicine programme (DMP)
Study: 32353110
Drug: Anticancer drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticancer drugs (19 identified drugs including lenalidomide, pomalidomide, nilotinib, ponatinib, midostaurin, azacytidine, clofarabine, docetaxel, obinutuzumab)
Study: 32354451
Drug: Subcutaneous implantable
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous implantable cardioverter-defibrillator (S-ICD) eligibility assessment
Study: 32355442
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with Oculofolin containing 900 µg L-methylfolate for three months
Study: 32355493
Drug: Ramucirumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (8 mg/kg every 2 weeks)
Study: 32355503
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) administration of alum-adjuvanted recombinant HBV vaccine
Study: 32355503
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of alum-adjuvanted recombinant HBV vaccine
Study: 32355836
Drug: Warfarin (VKA)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (VKA) with targeted INR 2-2.5
Study: 32357963
Drug: MTL-CEBPA (28-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTL-CEBPA (28-160 mg/m) administered intravenously once a week for 3 weeks followed by a rest period of 1 week per treatment cycle
Study: 32358769
Drug: Vagus Nerve
Normalized name: SUS SCROFA VAGUS NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagus Nerve Stimulation Therapy plus treatment-as-usual (VNS + TAU)
Study: 32359149
Drug: Type I
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type I Interferon (IFN-α) treatment
Study: 32359671
Drug: Civil commitment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Civil commitment for drug misuse
Study: 32360681
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of L-TAA and E-TAA
Study: 32361007
Drug: FDG-PET/CT guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG-PET/CT guided adaptive radiation therapy (4 Gy boost on top of 70 Gy baseline dose)
Study: 32361007
Drug: FDG-PET/CT guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG-PET/CT guided adaptive radiation therapy (78 Gy for partial metabolic response)
Study: 32361007
Drug: FDG-PET/CT guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG-PET/CT guided adaptive radiation therapy (74 Gy for complete metabolic response)
Study: 32361755
Drug: Oral cabotegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cabotegravir (30 mg/day)
Study: 32361755
Drug: Cabotegravir LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabotegravir LA (400 mg every 4 weeks or 600 mg every 8 weeks)
Study: 32362128
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) compliance measure (CCM)
Study: 32364230
Drug: Substituting 1
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substituting 1 tablespoon/d (8 g · 2000 kcal-1 · d-1) of soybean oil
Study: 32364844
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg spartalizumab intravenously, once every 4 weeks
Study: 32366324
Drug: 20% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% albumin infusion at 3 mL/kg over 30 min
Study: 32367609
Drug: Anal acoustic
Normalized name: Mephitis mephitis anal gland fluid preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anal acoustic reflectometry (AAR) before and after rectal distension with 100 ml of air
Study: 32367815
Drug: Daclatasvir 60
Normalized name: daclatasvir 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 60 mg once daily in combination with sofosbuvir 400 mg for 12 weeks
Study: 32367815
Drug: Daclatasvir 60
Normalized name: daclatasvir 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 60 mg once daily
Study: 32368162
Drug: Elbasvir/grazoprevir 50
Normalized name: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir/grazoprevir 50 mg/100 mg once daily for 12 weeks
Study: 32368217
Drug: Intralymphatic immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralymphatic immunotherapy (ILIT) with a single preseason booster of 1000 SQ-U Alutard 5-grasses
Study: 32368217
Drug: Intralymphatic immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralymphatic immunotherapy (ILIT) with standard dosing of 3000 SQ-U over 2 months
Study: 32368692
Drug: Mirabegron (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (a β3AR agonist)
Study: 32369480
Drug: Prednisone 40
Normalized name: prednisone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 40 mg daily for 3 days
Study: 32371540
Drug: sorafenib, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib, 400 mg twice daily
Study: 32371667
Drug: Nausea during
Normalized name: Pepto Nausea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nausea during treatment
Study: 32371801
Drug: Decreased insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decreased insulin resistance
Study: 32371801
Drug: Having triglycerides
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Having triglycerides above 150 mg/dl
Study: 32371801
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance index homeostatic model assessment